Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AIR-MAC study: Amikacin Liposome Inhalation Suspension for Mycobacterium Avium Complex Pulmonary Disease
jRCT1031250244Recruiting
- Start
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of amikacin liposome inhalation suspension in Mycobacterium avium-intracellulare infection (MAI), sponsored by none. Primary endpoints: Culture conversion rate at month 6 and Change in QOL-B score from baseline. Started Aug 2025; status: recruiting.
02
Drugs
amikacin liposome inhalation suspension
03
Conditions
Mycobacterium avium-intracellulare infection (MAI)
Beyond the preview
Go deeper on jRCT1031250244.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031250244.